Oncology (all articles)
State of the Art Review: Screening and prevention of colorectal cancer.
16 Sep, 2021 | 10:01h | UTCScreening and prevention of colorectal cancer – The BMJ (free for a limited period)
Related:
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
ACG Clinical Guidelines: Start colorectal cancer screening at 45
Guidelines for the surveillance and survivorship care of patients after curative treatment of colon and rectal cancer.
16 Sep, 2021 | 09:52h | UTC
Commentary on Twitter
Clinical Practice Guidelines – Surveillance and Survivorship shown in #DCRJournal visual abstract by @ianmpaquette @JMigaly @ASCRS_1. What do you think? https://t.co/e3kADOerpq@JISBMD @ConorDelaneyMD @justinmaykel @KarimAlavi @KyleCologne @dubaicolorectal @SamAtallahMD pic.twitter.com/wOhu0Mby60
— DCRjournal (@DCRjournal) May 9, 2021
Consensus Guideline: Liver transplantation for non-resectable colorectal liver metastases.
16 Sep, 2021 | 09:50h | UTCLiver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines – The Lancet Gastroenterology & Hepatology (free registration required)
Commentary on Twitter
New online – Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelineshttps://t.co/oZL4X4h7VS@IHPBA @gbonneysurg @eahpba @_ilts_#livertwitter #APHPBA_2021 pic.twitter.com/g6rrVclV5h
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) September 8, 2021
Systematic Review: Partial breast irradiation versus whole breast radiotherapy for early breast cancer.
15 Sep, 2021 | 08:46h | UTC
Commentary on Twitter
https://twitter.com/CochraneUK/status/1433703573402046467
RCT: Effect of Camrelizumab vs. placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma.
15 Sep, 2021 | 08:51h | UTCEffect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma—Renewed Enthusiasm and a Lingering Challenge – JAMA Oncology (free for a limited period)
Commentary on Twitter
Among patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of camrelizumab to chemotherapy, compared with placebo and chemotherapy, significantly improved overall survival and progression-free survival https://t.co/DAlhmtgvv1
— JAMA (@JAMA_current) September 14, 2021
Long-term report of study evaluating radiation following surgical excision for good-risk ductal carcinoma in situ.
14 Sep, 2021 | 08:44h | UTC
Commentary on Twitter
At 15 years, NRG-RTOG 9804 "good risk" breast #DCIS trial shows advantage of radiation therapy over observation to reduce #breastcancer risk https://t.co/l5OWVOb5Dg
#JCO #BCSM #radonc @NRGOnc; @MSK_RadOnc pic.twitter.com/TPAZRheoHT— Journal of Clinical Oncology (@JCO_ASCO) September 10, 2021
ESMO Guideline: Early and locally advanced non-small-cell lung cancer
14 Sep, 2021 | 08:42h | UTC
Review: neoadjuvant endocrine therapy in clinical practice.
12 Sep, 2021 | 21:34h | UTCNeoadjuvant Endocrine Therapy in Clinical Practice: A Review – JAMA Oncology (free for a limited period)
Systematic review finds there is insufficient evidence that AI breast cancer screening is accurate enough to replace human scrutiny.
10 Sep, 2021 | 05:12h | UTCOriginal study: Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy – The BMJ
Commentary on Twitter
A systematic review of #AI for mammography is very disappointing
"Thirty four (94%) of 36 AI systems evaluated in these studies were less accurate than a single radiologist, and all were less accurate than consensus of two or more radiologists"https://t.co/zqFTxojU9J @bmj_latest pic.twitter.com/wylwOsf4ua— Eric Topol (@EricTopol) September 2, 2021
Review: Cholangiocarcinoma.
10 Sep, 2021 | 05:02h | UTCCholangiocarcinoma – Nature Reviews Disease Primers (free for a limited period)
Infographic: Cholangiocarcinoma
Commentary on Twitter
Get Primed on #Cholangiocarcinoma with our NEW PrimeView! FREE to download this week! https://t.co/xw8yl29QI4 pic.twitter.com/JKtL6NqnlS
— Nature Reviews Disease Primers (@DiseasePrimers) September 9, 2021
Radiation‐induced cardiovascular disease: review of an underrecognized pathology.
9 Sep, 2021 | 08:54h | UTC
Pancreatic Cancer: A Review.
9 Sep, 2021 | 08:51h | UTCPancreatic Cancer: A Review – JAMA (free for a limited period)
Opinion | Liquid biopsy: misplaced faith in early cancer detection?
7 Sep, 2021 | 21:30h | UTCLiquid biopsy: misplaced faith in early cancer detection? – STAT
Commentary on Twitter
Opinion: "The real money isn’t in testing the relatively few people with advanced cancer, it’s in testing everyone else: those not known to have cancer." Screening liquid biopsies could become standard care before we know if they save lives https://t.co/1IAo5Kb0vm via @statnews
— Gideon Gil (@GideonGil) August 31, 2021
Antibiotics use is linked to increased risk of subsequent colorectal cancer.
7 Sep, 2021 | 21:25h | UTCCommentaries:
Antibiotics linked to increased risk of colon cancer – Umea University
Study links antibiotics use and increased subsequent risk of colorectal cancer – MedicalResearch.com
Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines.
7 Sep, 2021 | 10:34h | UTCCare of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines – ESMO Open
AAP Guideline: Long-term follow-up care for childhood, adolescent, and young adult cancer survivors.
3 Sep, 2021 | 10:17h | UTCLong-term Follow-up Care for Childhood, Adolescent, and Young Adult Cancer Survivors – Pediatrics
Brain and other central nervous system tumor statistics, 2021 – There were few improvements in the care of Glioblastoma in the past 4 decades. Specifically, the 5-year survival only increased from 4% to 7%.
1 Sep, 2021 | 08:58h | UTCBrain and other central nervous system tumor statistics, 2021 – CA: A Cancer Journal for Clinicians
Cohort study: Half of men with low-risk prostate cancer move from surveillance to treatment within a few years.
27 Aug, 2021 | 08:26h | UTC
Perspective: Toward personalized treatment approaches for non-small-cell lung cancer.
26 Aug, 2021 | 08:48h | UTCToward personalized treatment approaches for non-small-cell lung cancer – Nature Medicine (free for a limited period)
Commentary on Twitter
A Perspective published in @NatureMedicine discusses recent developments in non-small-cell lung cancer (NSCLC) immunotherapy and targeted therapies along with future directions for NSCLC management. https://t.co/iw5pG2zrmj pic.twitter.com/dfOEeO4dqo
— Nature Portfolio (@NaturePortfolio) August 21, 2021
Observational study suggests there is no need to provide a germ-free diet (neutropenic diet) for neutropenic high-risk patients with cancer.
26 Aug, 2021 | 08:45h | UTC
Related commentary on Twitter
🔥🔥 Dietary restriction meaningless in high-risk patients with cancer. Stop the tradition and restore patient autonomy & #QoL @jvehreschildgm1 @EricTopol @HallekMichael @mjvehreschild
Free download here https://t.co/n7NlE6RcQ7— Oliver Cornely (@CornelyOliver) August 14, 2021
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localized colon cancer.
26 Aug, 2021 | 08:33h | UTC
Guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery.
26 Aug, 2021 | 08:32h | UTC
Viewpoint: Sentinel lymph node biopsy in cutaneous melanoma—where do we stand?
22 Aug, 2021 | 22:16h | UTCSentinel Lymph Node Biopsy in Cutaneous Melanoma—Where Do We Stand? – JAMA Dermatology (free for a limited period)
Cohort study: Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers.
20 Aug, 2021 | 08:39h | UTC
Commentary on Twitter
For #BRCA1 mutation carriers, longer duration of oral contraceptive use (>10 yr) is associated with a greater reduction in #OvarianCancer risk, and the protection is long term. https://t.co/HrrutgaYKX
— Anna Chichura, MD (@AnnaChichuraMD) July 3, 2021
ASCO Guideline: Salivary gland hypofunction and/or xerostomia induced by nonsurgical cancer therapies.
19 Aug, 2021 | 08:50h | UTC